MARKET

CLDX

CLDX

Celldex Therapeutics Inc
NASDAQ
38.53
-1.10
-2.78%
Pre Market: 38.00 -0.53 -1.38% 08:00 04/19 EDT
OPEN
39.41
PREV CLOSE
39.63
HIGH
39.94
LOW
38.29
VOLUME
1
TURNOVER
0
52 WEEK HIGH
53.18
52 WEEK LOW
22.11
MARKET CAP
2.53B
P/E (TTM)
-13.1993
1D
5D
1M
3M
1Y
5Y
Health Care Sector Update for 04/17/2024: VNDA, CLDX, NRBO
NASDAQ · 1d ago
Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target
Benzinga · 1d ago
Celldex’s Barzolvolimab Shows Promise for Urticaria Treatment: A Strong Buy Recommendation
TipRanks · 1d ago
CELLDEX ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 STUDY OF BARZOLVOLIMAB IN PATIENTS WITH CHRONIC INDUCIBLE URTICARIA
Reuters · 2d ago
Weekly Report: what happened at CLDX last week (0408-0412)?
Weekly Report · 4d ago
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
NASDAQ · 04/09 13:35
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
NASDAQ · 04/08 16:00
More
About CLDX
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.

Webull offers Celldex Therapeutics, Inc. stock information, including NASDAQ: CLDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLDX stock methods without spending real money on the virtual paper trading platform.